Mutant fragments of OspA and methods and uses relating thereto
AssigneeValneva Austria GmbH
InventorsPär Comstedt, Markus Hanner, Urban Lundberg, Andreas Meinke, Wolfgang Schueler, Benjamin Wizel
Life of this patent
Estimating the term…
Abstract
The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
Claims12
A polypeptide comprising a mutant OspA fragment heterodimer selected from the group consisting of Lip-S1D1-S2D1 (SEQ ID NO:
- 186), Lip-S2D1-S1D1 (SEQ ID NO:
- 192), Lip-S1D1-S2D4 (SEQ ID NO:
- 198), and Lip-S2D4-S1D1 (SEQ ID NO:
- 203).
A polypeptide consisting of a mutant OspA fragment heterodimer selected from the group consisting of Lip-S1D1-S2D1 (SEQ ID NO:
- 186), Lip-S2D1-S1D1 (SEQ ID NO:
- 192), Lip-S1D1-S2D4 (SEQ ID NO:
- 198), and Lip-S2D4-S1D1 (SEQ ID NO:
- 203).
A pharmaceutical composition comprising Lip-S1D1-S2D1 (SEQ ID NO:
- 186), optionally, one or more additional mutant OspA fragment heterodimers, and optionally a pharmaceutically acceptable carrier or excipient.
Dependencies are inferred from the claim text.